Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний
- Название:Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний
- Автор:
- Жанр:
- Издательство:Эксмо
- Год:2021
- Город:Москва
- ISBN:978-5-04-155994-6
- Рейтинг:
- Избранное:Добавить в избранное
-
Отзывы:
-
Ваша оценка:
Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний краткое содержание
Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний - читать онлайн бесплатно ознакомительный отрывок
Интервал:
Закладка:
83. FAQs about the FDA Patient Representative Program. US Food and Drug Administration. www.fda.gov/ForPatients/ucm412529.htm. Updated May 12, 2018. Accessed March 19, 2019.
84. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996; Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
85. Historical evolution of FDA advisory committees. In: Rettig RA, Earley LE, Merill RA, eds. Institute of Medicine (US) Committee to Study the Use of Advisory Committees. National Academies Press; 1992.
Глава 8: В будущее с оптимизмом
1. FDA approved drugs for neurology. CenterWatch. www.centerwatch. com/drug-information/fda-approved-drugs/therapeutic-area/10/ neurology. Accessed November 29, 2018.
2. Там же.
3. Инструкция по применению: INBRIJA. US Food and Drug Administration. December 2018. www.accessdata.fda.gov/drugsatfda_ docs/label/2018/209184s000lbl.pdf.
4. Инструкция по применению: GOCOVRI. US Food and Drug Administration. August 2017. www.accessdata.fda.gov/drugsatfda_docs/ label/2017/208944lbl.pdf.
5. Инструкция по применению: XADAGO. US Food and Drug Administration. March 2017. www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf.
6. Инструкция по применению: NUPLAZID. US Food and Drug Administration. April 2016. www.accessdata.fda.gov/drugsatfda_docs/ label/2016/207318lbl.pdf.
7. Инструкция по применению: DUOPA. US Food and Drug
Administration. September 2016. www.rxabbvie.com/pdf/duopa_pi.pdf.
8. Инструкция по применению: RYTARY. US Food and Drug
Administration. January 2015. www.accessdata.fda.gov/drugsatfda_docs/ label/2015/203312s000lbl.pdf.
9. Инструкция по применению: NORTHERA. US Food and Drug Administration. February 2014. www.accessdata.fda.gov/drugsatfda_ docs/label/2014/203202lbl.pdf.
10. Novartis. Инструкция по применению: EXELON. US Food and Drug Administration. December 2018. www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/ files/exelon.pdf.
11. Инструкция по применению: NEUPRO. US Food and Drug Administration. April 2012. www.accessdata.fda.gov/drugsatfda_docs/ label/2012/021829s001lbl.pdf.
12. Инструкция по применению: APOKYN. US Food and Drug Administration. July 2014. www.accessdata.fda.gov/drugsatfda_docs/ label/2014/021264s010lbl.pdf.
13. Novartis. Инструкция по применению: COMTAN. US Food and Drug Administration. September 28, 2010. www.accessdata.fda.gov/ drugsatfda_docs/label/2010/020796s15lbl.pdf.
14. FDA approved drugs for neurology. CenterWatch. www.centerwatch. com/drug-information/fda-approved-drugs/therapeutic-area/10/ neurology. Accessed November 29, 2018.
15. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908.
16. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862; Wagle Shukla A, Okun MS. Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches. Neurotherapeutics. 2014;11(1):47–59.
17. Wagle Shukla A, Okun MS. Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches. Neurotherapeutics . 2014;11(1):47–59.
18. Alexander GE, Crutcher MD, DeLong MR. Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. In: Uylings HBM, Van Eden CG, De Bruin JPC, Corner MA, Feenstra MGP, eds. Progress in Brain Research. Vol 85. Elsevier; 1991:119–146; Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience. 1986;9(1):357–381.
19. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Stereotactic and Functional Neurosurgery. 1987;50(1–6):344–346.
20. Lozano AM, Eltahawy H. How does DBS work? Supplement to Clinical Neurophysiology . 2004;57:733–736.
21. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908; Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2010;362(22):2077–2091; Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurology. 2009;8(1):67–81; Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. New England Journal of Medicine. 2001;345(13):956–963; Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73; Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Archives of Neurology. 2011;68(2):165.
22. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019;15(4):234–242.
23. Medtronic Activa Tremor Control System. US Food and Drug Administration. Premarket Approval (PMA). www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P960009. Updated March 25,
2019. Accessed March 29, 2019.
24. Rossi PJ, Giordano J, Okun MS. The problem of funding off-label deep brain stimulation: bait-and-switch tactics and the need for policy reform. JAMA Neurology. 2017;74(1):9-10; Abosch A, Timmermann L, Bartley S, et al. An international survey of deep brain stimulation procedural steps. Stereotactic and Functional Neurosurgery. 2013;91(1):1-11.
25. Eberle W, Penders J, Yazicioglu RF. Closing the loop for deep brain stimulation implants enables personalized healthcare for Parkinson’s disease patients. Paper presented at the 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, August 30-September 3, 2011; Patel S, Mancinelli C, Hughes R, Dalton A, Shih L, Bonato P. Optimizing deep brain stimulation settings using wearable sensing technology. Paper presented at the 2009 4th International IEEE/EMBS Conference on Neural Engineering, April 29May 2, 2009.
26. Anidi C, O’Day JJ, Anderson RW, et al. Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson’s disease. Neurobiology of Disease. 2018;120:107–117; Malekmohammadi M, Herron J, Velisar A, et al. Kinematic adaptive deep brain stimulation for resting tremor in Parkinson’s disease. Movement Disorders . 2016;31(3):426–428.
27. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99-107.
28. Henderson R. The purple membrane from Halobacterium halobium. Annual Review of Biophysics and Bioengineering. 1977;6:87-109.
29. Там же.
30. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99-107.
31. Там же.; Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annual Review of Neuroscience. 2011;34(1):389–412.
32. Kravitz AV, Freeze BS, Parker PRL, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622–626.
33. Там же.
34. Там же.
35. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37.
36. Там же.
37. Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for Parkinson’s disease. Denali Therapeutics. August 1, 2018. http://investors.denalitherapeutics. com/ news-releases/ news-release-details/denali-therapeutics-announces-positive-clinical-results-lrrk2#ir-pages. Accessed November 29, 2018.
38. Denali Therapeutics announces first patient dosed in phase 1B study of DNL201 for Parkinson’s disease [пресс-релиз]. Denali Therapeutics, December 10, 2018; Study to evaluate DNL201 in subjects with Parkinson’s disease. US National Library of Medicine: ClinicalTrials. gov. https://clinicaltrials.gov/ct2/show/NCT03710707. Updated March 28, 2019. Accessed March 29, 2019.
39. Tracking LRRK2-Parkinson’s progression for better trial design. Alzforum. March 23, 2018. www.alzforum.org/news/research-news/ tracking-lrrk2-parkinsons-progression-better-trial-design. Accessed November 30, 2018.
40. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science . 2018;360(6384):36–37.
41. Там же.; Stott S. New LRRK2 results: game changer? Science of Parkinson’s. July 25, 2018. https://scienceofparkinsons.com/2018/07/25/lrrk-2. Accessed June 27, 2019; Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).
42. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).
43. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, Mc Inerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics. 2004;41(12):937–940.
44. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Frequency of known mutations in earlyonset Parkinson disease: implication for genetic counseling: the Consortium on Risk for Early-Onset Parkinson Disease study. Archives of Neurology. 2010;67(9):1116–1122.
45. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurology. 2012;11(11):986–998.
46. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Current Neurology and Neuroscience Reports. 2010;10(3):190–198.
47. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/ jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.
48. The Silverstein Foundation in the News. Silverstein Foundation for Parkinson’s with GBA. www.silversteinfoundation.org/in-the-news. Accessed March 29, 2019.
49. On the money. CNBC. August 19, 2017. https://archive.org/details/ CNBC_20170819_ 093000_On_the_Money.
50. Silverstein Foundation for Parkinson’s with GBA. 2018. www. silversteinfoundation.org. Accessed November 30, 2018.
Читать дальшеИнтервал:
Закладка:
